Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Tarsus Pharmaceuticals Stock (NASDAQ: TARS) stock price, news, charts, stock research, profile.
Open17.620 | Close17.890 |
Vol / Avg.273.861K / 462.930K | Mkt Cap583.462M |
Day Range17.220 - 17.970 | 52 Wk Range11.330 - 25.250 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | (EXPECTED) 2023-11-08 | |||||
REV | 510.000K |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.080 | -1.170 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-11 | Guggenheim | Eddie Hickman | Maintains | BuyBuy | Raises | 46.00 | 49.00 |
2023-08-14 | Guggenheim | Eddie Hickman | Reiterates | BuyBuy | Maintains | - | 46.00 |
2023-08-11 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Lowers | 50.00 | 42.00 |
2023-07-26 | HC Wainwright & Co. | Oren Livnat | Maintains | BuyBuy | Raises | 44.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
TARS | Tarsus Pharmaceuticals | 1.65% | 583.5M |
TBPH | Theravance Biopharma | 2.56% | 464.8M |
GHRS | GH Research | -12.23% | 504.1M |
SNDL | SNDL | 2.98% | 450.7M |
WVE | WAVE Life Sciences | -1.88% | 567.2M |
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL), WAVE Life Sciences (NASDAQ:WVE) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on Monday, September 11, 2023. The analyst firm set a price target for 49.00 expecting TARS to rise to within 12 months (a possible 173.90% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $17.89 last updated October 4, 2023 at 8:20 PM UTC.
There is no dividend information for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.